A Study to Evaluate the Persistence of the Antibody Response Elicited by 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Adults Who Have Previously Been Vaccinated With Either 2 Doses of 13vPnC or 13vPnC and 23-valent Pneumococcal Polysaccharide Vaccine in Different Sequential Order in Study 6115A1-3010 or 6115A1 3005

Trial Profile

A Study to Evaluate the Persistence of the Antibody Response Elicited by 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Adults Who Have Previously Been Vaccinated With Either 2 Doses of 13vPnC or 13vPnC and 23-valent Pneumococcal Polysaccharide Vaccine in Different Sequential Order in Study 6115A1-3010 or 6115A1 3005

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2011

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal vaccine
  • Indications Pneumococcal infections; Pneumonia
  • Focus Pharmacodynamics
  • Acronyms AB PERSISTENCE
  • Sponsors Pfizer
  • Most Recent Events

    • 15 Apr 2011 Status changed from recruiting to completed, ClinicalTrials.gov record.
    • 15 Jan 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov. (NCT01025336).
    • 09 Dec 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top